Recent results from a phase II prospective 2-year clinical trial in HER2+ breast cancer patients by Guglin and colleagues revealed that lisinopril and carvedilol appeared to offer a protective effect by attenuation of decline in EF in patients receiving combination AC and TRA [22, 23]. This evidence concerns the gene ERBB2 and breast carcinoma.